Cargando…

A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease

99mTc-sestamibi single photon emission tomography (SPECT) method is widely used for imaging coronary artery disease (CAD). 82-Rubidium-PET is an alternative method that can be used to perform the same purpose. PURPOSE/AIM: This study aims to determine whether 82-Rubidium-PET can offer extra value ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Alenezi, Meshaal M., Majrashi, Naif A., Sharif, Hayfa, Alyami, Ali S., Ageeli, Wael A., Salawi, Majed H., Refaee, Turkey A., Alanazi, Salem F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997794/
https://www.ncbi.nlm.nih.gov/pubmed/36897709
http://dx.doi.org/10.1097/MD.0000000000033068
_version_ 1784903329040564224
author Alenezi, Meshaal M.
Majrashi, Naif A.
Sharif, Hayfa
Alyami, Ali S.
Ageeli, Wael A.
Salawi, Majed H.
Refaee, Turkey A.
Alanazi, Salem F.
author_facet Alenezi, Meshaal M.
Majrashi, Naif A.
Sharif, Hayfa
Alyami, Ali S.
Ageeli, Wael A.
Salawi, Majed H.
Refaee, Turkey A.
Alanazi, Salem F.
author_sort Alenezi, Meshaal M.
collection PubMed
description 99mTc-sestamibi single photon emission tomography (SPECT) method is widely used for imaging coronary artery disease (CAD). 82-Rubidium-PET is an alternative method that can be used to perform the same purpose. PURPOSE/AIM: This study aims to determine whether 82-Rubidium-PET can offer extra value over 99mTc-sestamibi SPECT in imaging CAD. METHODS: To achieve the study aim, a systematic review of the literature for the 2 tracers were conducted. The aim of the systemic review was to find every related previous study that corresponded to well-defined scientific criteria. The analysis of the results was restricted to peer-reviewed papers in order to avoid any selective outcome reports. Besides, extra analysis was carried out to curb or avoid any ascertainment bias. The qualified studies selected for this research were then assessed for the risk of bias. Furthermore, the details of the methods were rechecked to ensure that they were comparable, before synthesizing the results. RESULTS: Eighteen original studies were selected and included in the final analysis out of 803 articles identified at the initial research. Overall, the mean value of sensitivity and specificity for diagnosis of CAD was 84.3% and 75.4%, respectively for technetium 99m sestamibi (99mTc-MIBI). On the other hand, for 82-Rubidium-PET, the mean value of sensitivity and specificity for diagnosis of CAD was 81% and 81%, respectively. The accuracy of diagnostics of these imaging modalities was dependent on the radiotracers and stress agent used in these studies, with 99mTc-MIBI achieving the highest diagnostic value. CONCLUSION: This study concludes that 99mTc-MIBI-SPECT has higher diagnostic value for diagnosing CAD compared to 82-Rubidium-PET. This indicates that 99mTc-MIBI-SPECT is a more valuable technique for predicting CAD. Besides, for the stress agents used to stimulate the heart and increase workload, this research/study recommends the use of adenosine for the SPECT and the use of dipyridamole for positron emission tomography. However, it suggests the need for more systemic and theoretical studies to assess the real value of 82-Rubidium-PET and the value of stress agents.
format Online
Article
Text
id pubmed-9997794
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99977942023-03-10 A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease Alenezi, Meshaal M. Majrashi, Naif A. Sharif, Hayfa Alyami, Ali S. Ageeli, Wael A. Salawi, Majed H. Refaee, Turkey A. Alanazi, Salem F. Medicine (Baltimore) 3400 99mTc-sestamibi single photon emission tomography (SPECT) method is widely used for imaging coronary artery disease (CAD). 82-Rubidium-PET is an alternative method that can be used to perform the same purpose. PURPOSE/AIM: This study aims to determine whether 82-Rubidium-PET can offer extra value over 99mTc-sestamibi SPECT in imaging CAD. METHODS: To achieve the study aim, a systematic review of the literature for the 2 tracers were conducted. The aim of the systemic review was to find every related previous study that corresponded to well-defined scientific criteria. The analysis of the results was restricted to peer-reviewed papers in order to avoid any selective outcome reports. Besides, extra analysis was carried out to curb or avoid any ascertainment bias. The qualified studies selected for this research were then assessed for the risk of bias. Furthermore, the details of the methods were rechecked to ensure that they were comparable, before synthesizing the results. RESULTS: Eighteen original studies were selected and included in the final analysis out of 803 articles identified at the initial research. Overall, the mean value of sensitivity and specificity for diagnosis of CAD was 84.3% and 75.4%, respectively for technetium 99m sestamibi (99mTc-MIBI). On the other hand, for 82-Rubidium-PET, the mean value of sensitivity and specificity for diagnosis of CAD was 81% and 81%, respectively. The accuracy of diagnostics of these imaging modalities was dependent on the radiotracers and stress agent used in these studies, with 99mTc-MIBI achieving the highest diagnostic value. CONCLUSION: This study concludes that 99mTc-MIBI-SPECT has higher diagnostic value for diagnosing CAD compared to 82-Rubidium-PET. This indicates that 99mTc-MIBI-SPECT is a more valuable technique for predicting CAD. Besides, for the stress agents used to stimulate the heart and increase workload, this research/study recommends the use of adenosine for the SPECT and the use of dipyridamole for positron emission tomography. However, it suggests the need for more systemic and theoretical studies to assess the real value of 82-Rubidium-PET and the value of stress agents. Lippincott Williams & Wilkins 2023-03-10 /pmc/articles/PMC9997794/ /pubmed/36897709 http://dx.doi.org/10.1097/MD.0000000000033068 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 3400
Alenezi, Meshaal M.
Majrashi, Naif A.
Sharif, Hayfa
Alyami, Ali S.
Ageeli, Wael A.
Salawi, Majed H.
Refaee, Turkey A.
Alanazi, Salem F.
A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease
title A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease
title_full A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease
title_fullStr A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease
title_full_unstemmed A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease
title_short A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease
title_sort systemic review of rubidium-82 pet contrasted with 99mtc-mibi spect for imaging coronary artery disease
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997794/
https://www.ncbi.nlm.nih.gov/pubmed/36897709
http://dx.doi.org/10.1097/MD.0000000000033068
work_keys_str_mv AT alenezimeshaalm asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT majrashinaifa asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT sharifhayfa asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT alyamialis asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT ageeliwaela asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT salawimajedh asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT refaeeturkeya asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT alanazisalemf asystemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT alenezimeshaalm systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT majrashinaifa systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT sharifhayfa systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT alyamialis systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT ageeliwaela systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT salawimajedh systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT refaeeturkeya systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease
AT alanazisalemf systemicreviewofrubidium82petcontrastedwith99mtcmibispectforimagingcoronaryarterydisease